Hansa Biopharma AB (0RC7)
London Exchange · UK · prices in SEK · close of 21 Oct 2026
Key indicators
| Last close | SEK 37.51 |
|---|---|
| 52-week range | 23.57 – 48.00 |
| Return, 1 month / 3 months | +5.4% / +21.3% |
| Return, 1 year / 3 years | +14.4% / +5.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 56 |
| Volatility (1 year) | 66.2% |
| Worst drawdown (1 year) | -42.0% |
| Average daily value traded | 0.21M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Hansa Biopharma AB is a biopharmaceutical company based in Lund, Sweden, that develops enzyme-based medicines for people with rare immunological conditions. Its main product is an enzyme that breaks down immunoglobulin G antibodies, and the company also works on antibody-modulating therapies and diagnostics in transplantation and autoimmune disease. Its customers are hospital specialists and transplant centres, and its work centres on helping patients who need desensitisation before organ transplants or treatment for antibody-mediated disorders.
The shares are listed on the London Exchange in UK under the code 0RC7, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Hansa Biopharma AB (0RC7) trades on the London Exchange in UK. It last closed at SEK 37.51 on 21 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 1,846 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.4% and over the last three months it rose 21.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.6% | ||
| From 52-week high | -19.2% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 21.3% | ||
| 6-month return | 57.9% | ||
| 12-month return, skipping the last month | 8.5% | ||
| Stability (higher is calmer) | 22 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 66.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -42.0% | ||
| Liquidity | 37 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.21M SEK | ||
| Zero-volume days | 16.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +6.3% |
|---|---|
| 1 month | +5.4% |
| 3 months | +21.3% |
| 6 months | +57.9% |
| 1 year | +14.4% |
| 3 years | +5.9% |
| 5 years | – |
Signals
| 50-day / 200-day average | 38.70 / 34.23 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.27 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.